

May 29, 2024

To,
THE MANAGER,
LISTING DEPARTMENT,
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
'EXCHANGE PLAZA', BANDRAKURLA COMPLEX,
BANDRA (EAST), MUMBAI 400 051.
NSE SYMBOL: INFINIUM

Dear Sir/Madam,

Sub: Outcome of Board Meeting

This is to inform you under Regulation 30 and any other Regulation of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. With reference to the captioned subject and in furtherance to our intimation letter dated May 22, 2024, we hereby inform the stock exchange that the Board of Directors of the company at its meeting held today i.e. **Wednesday May 29, 2024** inter-alia decided as under:

1. Considered and approved the standalone audited financial results of the Company for the year ended on March 31, 2024.
2. Considered and approved the consolidated audited financial results of the Company for the year ended on March 31, 2024.
3. Considered and approved the appointment of Mr. Piyush P Sutariya & Co. Chartered Accountant as internal auditor for the Financial Year 2024-25.
4. Considered and approved the appointment of M/s RTBR & Associates as Secretarial auditor for the Financial Year 2024-25.
5. Approved criteria for granting omnibus approval for related party transactions for F.Y. 2024-25.

Kindly note that the meeting of the Board of Directors of the Company commenced at **11:45 a.m.** and concluded at **02:10 p.m.**

We request you to kindly take the same on record.

Thanking You,

Yours Sincerely,

FOR INFINIUMPHARMACHEM LIMITED

SANJAYKUMARVITHTHALBHAI PATEL
MANAGING DIRECTOR
DIN: 00370715
Encl.: A/a.

Annexure A

DECLARATION

Under regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended by SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016, read with SEBI circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016,

It is hereby declared and confirmed that the Auditors' Report on Annual Audited Standalone financial results for the year ended on March 31, 2024 and Annual Audited Consolidated financial results for the year ended on March 31, 2024 of the company is with unmodified opinion.

We further declare that M/s Ashok Rajpara & Co., Chartered Accountants (FRN : 153195W), the Statutory Auditors of the Company have issued an Audit Report with unmodified opinion on the audited Standalone and Consolidated financial results of the Company for the period ended on March 31, 2024.

This declaration is issued in compliance of Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 as amended by the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2016.

Kindly take the same on your record.

FOR INFINIUMPHARMACHEM LIMITED

SANJAYKUMARVITHTHALBHAI PATEL
MANAGING DIRECTOR
DIN: 00370715

Date: May 29, 2024

Place: Anand

ASHOK RAJPARA & CO

Chartered Accountants

INDEPENDENT AUDITORS' REPORT on Audited Standalone yearly financial Results of INFINIUM PHARMACHEM LIMITED Pursuant to the Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board Of Directors of
INFINIUM PHARMACHEM LIMITED
Plot No. 37-38, Sojitra GIDC,
Dist : Anand, Gujarat

Opinion

We have audited the accompanying standalone annual financial results of INFINIUM PHARMACHEM LIMITED ("the company"), for the year ended 31st March, 2024 attached herewith, being submitted by the company pursuant to the requirements of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations') including relevant circulars issued by the Securities and Exchange Board of India (SEBI) from time to time.

In our opinion and to the best of our information and according to the explanations given to us, the statement:

- i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- ii. Gives a true and fair view in conformity with the recognition and measurement principles laid down in the accounting principles generally accepted in India of the state of affairs of the company as at 31st March 2024, its profit, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the standalone financial statements in accordance with the standards on Auditing specified under Section 143(10) of the Act. Our responsibility under those standards are further described in Auditor's Responsibility for the Audit of the standalone financial statements section of our report. We are independent of the company in accordance of with code of ethics issued by ICAI together with the independent requirements that are relevant to our audit of standalone financial statement under the provisions of the Act and the rule made there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the stand-alone financial statement.

The Company is listed w.e.f. 17th April, 2023 and Half yearly results during the financial year 2022-23 are not applicable and hence not provided.

ASHOK RAJPARA & CO.
M.NO. 100559
CHARTERED ACCOUNTANTS

ASHOK RAJPARA & CO

Chartered Accountants

Management's and Those Charged with Governance Responsibilities for the Statement

This statement has been prepared on the basis of the standalone annual financial statements. The company's Board of Directors is responsible for the preparation and presentation of the statement that gives a true and fair view of the net profit/loss and other financial information of the company in accordance with the accounting principles generally accepted in India, including AS prescribed under section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations including SEBI circular. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the statement that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the statement, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibility

Our objectives are to obtain reasonable assurance about whether standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is high level of assurance, but is not a guarantee that an audit conducted in accordance with SAS will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decision of users taken on the basis of these standalone financial statements.

As a part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit, We also;

- Identify and assess the risk of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedure responsive to those risk, and obtain evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omission, misrepresentation, or the override of internal control.
- Obtain an understanding of internal financial control relevant to the audit in order to design audit procedure that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are

ASHOK RAJPARA & CO

Chartered Accountants

also responsible for expressing our opinion on whether the company has adequate internal financial control system in place and the operating effectiveness of such controls.


- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

we also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

FOR, ASHOK RAJPARA & CO

Chartered Accountants



(Ashok M. Rajpara)

Proprietor

Membership No. 100559

FRN : 153195W

UDIN :

24100559BKDFBD4101

Place: Vallabh Vidhyanagar

Date : 29/05/2024

ASHOK RAJPARA & CO.
M.NO. 100559
CHARTERED ACCOUNTANTS

STATEMENT OF STANDALONE FINANCIAL RESULT FOR THE YEAR ENDED ON 31ST MARCH, 2024

PARTICULARS	Half- year ended		(Rs. In Lacs)	
	31.03.2024	30.09.2023	31.03.2024	31.03.2023
	Audited	Unaudited	Audited	Audited
INCOME				
Revenue from Operations	7150.53	5085.24	12235.77	10130.62
Other Income, net	128.96	33.76	162.72	134.34
TOTAL INCOME	7279.49	5119.00	12398.49	10264.96
EXPENSES				
Cost of Material Consumed	5982.69	3818.16	9800.85	7152.53
Purchases of Traded Goods	0	0.00	0.00	0.00
Changes In Inventories of FG., WIP.	-190.69	-239.72	-430.41	-96.79
Employee Benefits Expenses	247.04	208.57	455.61	366.62
Financial Cost	92.54	84.96	177.5	299.65
Depreciation and Amortization Expenses	126.46	114.49	240.95	128.91
Other Expenses	352.66	315.3	667.96	1187.56
TOTAL EXPENSES	6610.7	4301.76	10912.46	9038.47
Profit Before exceptional and extraordinary Items	668.79	817.24	1486.03	1226.49
Exceptional Items	0	0.00	0.00	0.00
Profit Before Taxes	668.79	817.24	1486.03	1226.49
Tax Expenses				
(a) Current Tax	159.94	207.2	367.14	309.09
(b) Deferred Tax (Liabilities)/Assets	-12.83	1.47	-11.36	1.58
(c) Prior Year Tax (Liabilities)/Assets	0	1.80	1.80	0.90
Profit (Loss) for the period	496.02	613.31	1109.33	914.92
Earning per equity share				
(a) Basic	3.56	4.41	7.97	18.00
(b) Dilluted	3.56	4.41	7.97	18.00

Notes For Standalone Financial Results :

- The above audited Standalone Financial Results of Infinium Pharmachem Limited for the year ended on 31st March 2024 were revived and recommended by the Audit committee and approved by the Board of Directors, at their respective meeting held on 29th May, 2024
- The above Standalone Financial Results of Infinium Pharmachem Limited for the year ended on 31st March 2024 are prepared in accordance with the Accounting Standards Prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies Rules, 2014 as amended) and other recognised accounting practices and policies, as applicable.
- The Company is listed w.e.f. 17th April, 2023 and half yearly result for the half year ended on 31st March, 2023 are not applicable to the
- The company had made an initial public issue (SME -IPO) of 18,75,000 equity shares of face vale of Rs. 10/- fully paid up for cash at a price of Rs 135/- per equity share including share premium of Rs. 125/- per equity share) aggregating to Rs. 2525.72 Lakhs. SME- IPO opened for public on 31st March 2023 and listed on NSE -SME Platform on 17th April, 2023.
- During the year, the Board at its meeting held on 14th September, 2023 approved allotment of 69,58,060 equity shares of Rs. 10 as bonus shares in the ratio of 1:1 to eligible shareholders as on record date i.e. 13th September, 2023
- The Financial results include the results for the Half year ended March 31, 2024, being the balancing figure between Audited figures in respect of full financial year and the
- The Company has only one reported business segment viz. Chemicals, accordingly segment reporting is not required.
- In accordance with regulation 33 of SEBI (LODR) Regulation 2015, the above result have been audited by the Statutory Auditors of the

Place : Vallabh Vidhyanagar
Date : 29/05/2024

For, INFINIUM PHARMACHEM LTD

Sanjay V Patel
Chairman
DIN No. : 00370715



STATEMENT OF STANDALONE ASSETS AND LIABILITIES

PARTICULAR	(Rs. In Lacs)	
	As At 31.03.2024	As At 31.03.2023
	Audited	Audited
A. ASSETS		
1. NON CURRENT ASSETS		
(a) Property, Plant and Equipment	1646.91	1558.03
(b) Intangible Assets	0	0.00
(c) Capital Work in Progress	1.50	0.00
(d) Intangible Assets under development	0	0.00
(e) Non Current Investments	34.11	34.11
(f) Deffered Tax assets(Net)	0	5.16
(g) Long term Loans and Advances	31.91	31.10
(h) Other Assets	37.01	13.00
Total Non Current Assets	1751.44	1641.39
2. CURRENT ASSETS		
(a) Inventories	2248.21	1791.34
(b) Financial Assets		
(i) Current Investments	0	0.00
(ii) Trade Receivable	2381.08	1516.02
(iii) Cash and Cash Equivalents	817.59	331.51
(iv) Other Balance With Banks	0.06	0.06
(v) Loans and Advances	546.79	739.16
(vi) Other Asstes	29.07	22.33
Total Current Assets	6022.8	4400.44
TOTAL ASSETS	7774.24	6041.83
B. EQUITY AND LIABILITIES		
1. EQUITY		
(a) Equity Share Capital	1391.61	508.31
(b) Other Equity	4383.71	1661.59
Total Equity	5775.32	2169.89
2. LIABILITY		
NON-CURRENT LIABILITIES		
(a) Financial Liabilities	0	0.00
(b) Deferred Tax Liabilities	6.21	0.00
(c) Other Non Current Liabilities	544.05	763.05
Total Non Current Liabilities	550.26	763.05
CURRENT LIABILITIES		
(a) Financial Liabilities		
(i) Trade Payables	750.23	877.82
(1) Total outstanding dues of MSME.	42.46	20.65
(2) Total outstanding dues Otherthan MSME.	707.77	857.17
(ii) Other Financial Liabilities	250.04	1846.45
(b) Other Current Liabilities	5.78	0.72
(c) Provisions	75.47	74.81
(d) Income tax Liabilities	367.14	309.09
Total Current Liabilities	1448.66	3108.89
TOTAL	7774.24	6041.83

For, INFINIUM PHARMACHEM LTD

Place : Vallabh Vidhyanagar
Date : 29/05/2024



Sanjay V Patel
Chairman
DIN No. : 00370715

STANDALONE CASH FLOW STATEMENT FOR THE YEAR ENDED ON 31ST MARCH, 2024

Particular	(Rs. In Lacs)	
	For the Year ended 31st March, 2024	For the Year ended 31st March, 2023
A. Cash Flow from Operating Activities		
Net Profit / (Loss) before Tax	1486.03	1226.49
Adjustments for :		
Depreciation and Amortization	240.95	128.91
Financial Cost	177.50	299.65
Interest Received	(27.00)	(1.34)
Other Non Operating income	0.00	0.00
Operating Profit before working capital changes	1877.48	1653.71
Adjustments for (increase)/Decrease in operating assets :		
Trade Receivable	(865.06)	(221.15)
Inventories	(456.87)	(368.63)
Loans and Advances	192.38	(272.79)
Other Current Assets	(6.73)	32.55
Adjustments for increase/(Decrease) in operating liabilities :		
Trade Payable	(127.59)	(147.10)
Other Non Current Liabilities	(212.80)	(599.33)
Other Financial Liabilities- Current	(1596.40)	956.77
Other Current Liabilities	5.06	(14.24)
Provisions	58.71	25.15
Increase / (Decrease) in Non Current Assets		
Cash Generated From Operations	(1131.83)	1044.94
Direct Tax	365.34	309.99
Indirect Tax		
Net Cash From Operating Activities (A)	(1497.17)	734.94
B. Cash Flow from Investing Activities		
Purchase of Tangible Fixed Assets (Gross)	(331.33)	(464.68)
Purchase of Intangible Fixed Assets (Gross)	0.00	0.00
Increase / (Decrease) in Non Current Assets	0.00	0.00
Long term Loans and Advances	(0.81)	(19.68)
Other Non Current Assets	(24.02)	232.48
Other Non Current Investments	0.00	(7.65)
Interest Received	27.00	1.34
Other Non Operating income	0.00	0.00
Net Cash used in Investing Activities (B)	(329.16)	(258.20)
C. Cash Flow from Financing Activities		
Proceeds from Issuing share	2525.71	0.00
Share Premium Utilised in W/off IPO Expenses	(29.61)	0.00
Interest /Finacial Charges Paid	(177.50)	(299.65)
Net Cash used in Financing Activities (c)	2318.60	(299.65)
Net Increase / (Decrease) in cash and cash equivalents (A+B+C)	492.28	177.09
Cash and cash equivalents at the beginning of the year	331.58	154.48
Cash and cash equivalents at the end of the year	823.85	331.58

For, INFINIUM PHARMACHEM LTD.

Place : Vallabh Vidhyanagar
Date : 29/05/2024



Sanjay V Patel
Chairman
DIN No. : 00370715

ASHOK RAJPARA & CO

Chartered Accountants

INDEPENDENT AUDITORS' REPORT on Audited Consolidated yearly financial Results of pursuant to the Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board Of Directors of
INFINIUM PHARMACHEM LIMITED
Plot No. 37-38, Sojitra GIDC,
Dist : Anand, Gujarat

Opinion

We have audited the accompanying consolidated annual financial results of INFINIUM PHARMACHEM LIMITED ("the Holding Company) and its subsidiaries (the Holding Company and its subsidiary together referred to as " Group") FOR THE YEAR ENDED 31ST March 2024, attached herewith, pursuant to the requirements of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations') including relevant circulars issued by the Securities and Exchange Board of India (SEBI) from time to time.

In our opinion and to the best of our information and according to the explanations given to us, the statement :

- i. Includes the result of following subsidiary :
 - a) Infinium Green Energy Private Limited
 - b) Shanghai Tajilin Industrial Co. Limited
- ii. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- iii. Gives a true and fair view in conformity with the recognition and measurement principles laid down in the accounting principles generally accepted in India of the state of affairs of the company as at 31st March 2024, its profit, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the consolidated financial statements in accordance with the standards on Auditing specified under Section 143(10) of the Act. Our responsibility under those standards are further described in Auditor's Responsibility for the Audit of the consolidated financial statements section of our report. We are independent of the company in accordance of with code of ethics issued by ICAI together with the independent requirements that are relevant to our audit of consolidated financial statement under the provisions of the Act and the rule made there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the stand-alone financial statement.

The Company is listed w.e.f. 17th April, 2023 and Half yearly results during the financial year 2022-23 are not applicable and hence not provided.

Management's and Those Charged with Governance Responsibilities for the Statement

This consolidated statement has been prepared on the basis of the standalone annual financial statements. The company's Board of Directors is responsible for the preparation and presentation of the statement that gives a true and fair view of the net profit/loss and other financial information of the company in accordance with the accounting principles generally accepted in India, including AS prescribed under section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations including SEBI circular. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the statement that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the consolidated statement, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibility

Our objectives are to obtain reasonable assurance about whether consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is high level of assurance, but is not a guarantee that an audit conducted in accordance with SAS will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decision of users taken on the basis of these consolidated financial statements.

As a part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit, We also;

- Identify and assess the risk of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedure responsive to those risk, and obtain evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omission, misrepresentation, or the override of internal control.

ASHOK RAJPARA & CO

Chartered Accountants

- Obtain an understanding of internal financial control relevant to the audit in order to design audit procedure that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial control system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

we also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

ASHOK RAJPARA & CO.
M.NO. 100559
CHARTERED ACCOUNTANTS

ASHOK RAJPARA & CO

Chartered Accountants

Other Matter

The consolidated financial statement includes the unaudited financial results/financial information of one foreign subsidiary, whose financial result/financial information reflects total assets of Rs. 83063.12 thousands as at March 31, 2024, total revenue of Rs. 258993.63 thousands, net profit after tax of Rs. 4319.46 thousands for the year ended on that date, as considered in the consolidated financial statements, which have not been audited by its auditor. The subsidiary financial statements have been consolidated based on its management certified accounts.

FOR, ASHOK RAJPARA & CO

Chartered Accountants

ASHOK RAJPARA & CO.
M.NO. 100559
CHARTERED ACCOUNTANTS



(Ashok M. Rajpara)

Proprietor

Membership No. 100559

FRN : 153195W

UDIN : 24100559BKDFBE 5538

Place: Vallabh Vidhyanagar

Date : 29/05/2024

STATEMENT OF CONSOLIDATED FINANCIAL RESULT FOR THE YEAR ENDED ON 31ST MARCH, 2024

(Rs. In Lacs)

PARTICULARS	Half- year ended		Year ended	
	31.03.2024	30.09.2023	31.03.2024	31.03.2023
	Audited	Unaudited	Audited	Audited
INCOME				
Revenue from Operations	7417.69	6148.19	13565.88	11422.49
Other Income, net	120.36	33.80	154.16	135.16
TOTAL INCOME	7538.05	6181.99	13720.04	11557.64
EXPENSES				
Cost of Material Consumed	6039.37	3843.23	9882.60	7152.53
Purchases of Traded Goods	98.33	824.03	922.36	864.44
Changes In Inventories of FG., WIP.	-298.53	-196.04	-494.57	40.14
Employee Benefits Expenses	373.83	217.25	591.08	537.11
Financial Cost	112.76	106.37	219.13	310.48
Depreciation and Amortization Expenses	142.01	124.78	266.79	133.88
Other Expenses	378.61	433.04	811.65	1223.76
TOTAL EXPENSES	6846.38	5352.66	12199.04	10262.34
Profit Before Exceptional & Extraordinary Items	691.67	829.33	1521.00	1295.30
Exceptional Items	0.00	0.00	0.00	0.00
Profit Before Taxes	691.67	829.33	1521.00	1295.30
Tax Expenses				
(a) Current Tax	160.13	208.88	369.01	311.09
(b) Deffered Tax (Liabilities)/Assets	-9.39	5.89	-3.50	1.58
(c) Prior Year Tax (Liabilities)/Assets	0.00	1.80	1.80	0.90
Profit after tax for the year	522.15	628.14	1150.29	981.73
Less : Non Controlling Interest	12.80	7.27	20.07	32.74
Profit (Loss) for the period	509.35	620.87	1130.22	948.99
Earning per equity share				
(a) Basic	3.66	4.46	8.12	18.67
(b) Dilluted	3.66	4.46	8.12	18.67

Notes For Consolidated Financial Results :

- The above audited Consolidated Financial Results of Infinium Pharmachem Limited for the year ended on 31st March 2024 were reviewed and recommended by the Audit committee and approved by the Board of Directors, at their respective meeting held on 29th May, 2024
- The above Consolidated Financial Results of Infinium Pharmachem Limited for the year ended on 31st March 2024 are prepared in accordance with the Accounting Standards Prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies Rules, 2014 as amended) and other recognised accounting practices and policies, as applicable.
- Following subsidiary company has been considered in the preparation of consolidated financial statements for the year ended on 31st March, 2024

Name of the entity	Country Of Incorporation	% Of Holding
Shanghai Tajilin Industrial Co. Limited	China	51%
Infinium Green Energy Private Limited	India	51%

- The Company is listed w.e.f. 17th April, 2023 and Half yearly Results during the financial year 2022-23 are not applicable and hence not provided.
- The company had made an initial public issue (SME -IPO) of 18,75,000 equity shares of face vale of Rs. 10/- fully paid up for cash at a price of Rs 135/- per equity share including share premium of Rs. 125/- per equity share) aggregating to Rs. 2525.72 Lakhs. SME- IPO opened for public on 31st March,2023 and listed on NSE -SME Platform on 17th April, 2023.
- During the year, the Board at its meeting held on 14th September, 2023 approved allotment of 69,58,060 equity shares of Rs. 10 as bonus shares in the ratio of 1:1 to eligible shareholders as on record date i.e. 13th September, 2023
- The Financial Results include the Results for the Half year ended March 31, 2024, being the balancing figure between Audited figures in respect of full financial year and the published unaudited year to date figures up to the first half of the current financial year which were subjected to limited review by
- The Company has only one reported business segment viz. Chemicals, accordingly segment reporting is not required.
- In accordance with regulation 33 of SEBI (LODR) Regulation 2015, the above result have been audited by the Statutory Auditors of the Company.

Place : Vallabh Vidhyanagar
Date : 29/05/2024



For, **INFINIUM PHARMACHEM LTD**

Sanjay V Patel
Chairman
DIN No. : 00370715

STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES

PARTICULARS	(Rs. In Lacs)	
	For the year ended on 31st March,2024	For the year ended on 31st March,2023
A. ASSETS		
I. NON CURRENT ASSETS		
(a) Property, Plant and Equipment	1963.53	1880.64
(b) Intangible Assets	0	0.00
(c) Capital Work in Progress	1.5	0.00
(d) Intangible Assets under development	0	0.00
(e) Non Current Investments	0	0.00
(f) Deferred Tax assets(Net)	1.66	5.16
(g) Long term Loans and Advances	35.53	31.10
(h) Other Assets	41.92	13.00
Total Non Current Assets	2044.14	1929.90
2. CURRENT ASSETS		
(a) Inventories	2469.45	1971.72
(b) Financial Assets		
(i) Current Investments	0	0.00
(ii) Trade Receivable	2045.18	1543.23
(iii) Cash and Cash Equivalents	1191.14	597.95
(iv) Other Balance With Banks	0.06	0.06
(v) Loans and Advances	563.83	679.79
(vi) Other Asstes	231.36	338.56
Total Current Assets	6501.020	5131.31
TOTAL ASSETS	8545.160	7061.22
B. EQUITY AND LIABILITIES		
1. EQUITY		
(a) Equity Share Capital	1391.61	508.31
(b) Other Equity	4486.33	1747.83
	5877.94	2256.13
(c) Non Controlling Interest	145.35	122.07
Total Equity	6023.29	2378.20
2. LIABILITY		
NON-CURRENT LIABILITIES		
(a) Financial Liabilities	0	0.00
(b) Deferred Tax Liabilities	0	0.00
(c) Other Non Current Liabilities	789.14	1006.11
Total Non Current Liabilities	789.14	1006.11
CURRENT LIABILITIES		
(a) Financial Liabilities		
(i) Trade Payables	451.3	682.77
(ii) Other Financial Liabilities	335.3	1917.88
(b) Other Current Liabilities	487.01	682.56
(c) Provisions	91.98	84.61
(d) Income tax Liabilities	367.14	309.09
Total Current Liabilities	1732.73	3676.91
TOTAL	8545.16	7061.22
For, INFINIUM PHARMACHEM LTD		
Place : Vallabh Vidhyanagar	 Sanjay V Patel Chairman DIN No. : 00370715	
Date : 29/05/2024		

CONSOLIDATED CASH FLOW STATEMENT FOR THE YEAR ENDED ON 31T MARCH, 2024

Particular	(Rs. In Lacs)	
	For the Year ended 31st March, 2024	For the Year ended 31st March, 2023
A. Cash Flow from Operating Activities		
Net Profit / (Loss) before Tax	1,521.01	1295.30
Adjustments for :		
Depreciation and Amortization	266.79	133.88
Financial Cost	219.14	310.48
Interest Received	18.17	1.96
Other Adjustment non cash items -currency fluctuation rereserve	-4.52	(3.08)
Non Controlling Interest	-20.07	(32.74)
Other Non Operating income		
Operating Profit before working capital changes	2,000.52	1705.80
Adjustments for (increase)/Decrease in operating assets :		
Trade Receivable	-501.96	(4.04)
Inventories	-497.73	(335.60)
Loans and Advances	115.97	(186.86)
Other Current Assets	107.21	(183.55)
Adjustments for increase/(Decrease) in operating liabilities :		
Trade Payable	-231.48	(498.91)
Other Non Current Laibilities	-216.97	(356.27)
Other Financial Liabilities- Current	-1,582.57	1028.19
Other Current Liabilities	-195.55	(29.16)
Provisions	65.42	31.37
Increase / (Decrease) in Non Current Assets		
Cash Generated From Operations	-937.13	1170.96
Direct Tax	367.22	311.99
Indirect Tax		
Net Cash From Operating Activities (A)	-1,304.35	858.96
B. Cash Flow from Investing Activities		
Purchase of Tangible Fixed Assets (Gross)	-351.18	(746.62)
Purchase of Intangible Fixed Assets (Gross)	0.00	0.00
Increase / (Decrease) in Non Current Assets	0.00	0.00
Non controlling Interest (BS)	23.28	40.14
Long term Loans and Advances	-4.43	(19.68)
Other Non Current Assets	-28.92	232.48
Interest Received	-18.17	(1.96)
Other Non Operating income	0.00	0.00
Net Cash used in Investing Activities (B)	-379.42	(495.64)
C. Cash Flow from Financing Activities		
Proceeds from Issuing share	2,525.71	0.00
IPO Expenses W/off	-29.61	0.00
Interest /Finacial Charges Paid	-219.14	(310.48)
Net Cash used in Financing Activities (C)	2,276.97	(310.48)
Net Increase / (Decrease) in cash and cash equivalents	593.19	52.85
Cash and cash equivalents at the beginning of the year	598.01	545.16
Cash and cash equivalents at the end of the year	1,191.21	598.01

For, INFINIUM PHARMACHEM LTD

Place : Vallabh Vidhyanagar
Date : 29/05/2024



Sanjay V Patel
Chairman
DIN No. : 00370715